Related Experiment Video
Updated: Mar 21, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Potential role for metformin in urologic oncology
Rashid Khalid Sayyid1, Neil Eric Fleshner1
1Department of Urology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Abstract:
Metformin is one of the most commonly used drugs worldwide. It is currently considered first-line pharmacological agent for management of diabetes mellitus type 2. Recent studies have suggested that metformin may have further benefits, especially in the field of urologic oncology. Use of metformin has been shown to be associated with decreased incidence and improved outcomes of prostate, bladder, and kidney cancer. These studies suggest that metformin does have a future role in the prevention and management of urologic malignancies. In this review, we will discuss the latest findings in this field and its implications on the management of urologic oncology patients.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Urinary Tract Calculi III: Medical Management
Oral Hypoglycemic Agents: Sulfonylureas
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

